Tolga Çiftpınar
Research Subjects
Tolga Çiftpınar has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Adil Barut
1 shared publication- Ahmet Emin Mutlu
Hüma Kadın Hastalıkları ve Doğum Hastanesi
1 shared publication - Aidana Sharip Kyzy
SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL BAŞAKŞEHİR ÇAM VE SAKURA ŞEHİR SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ
1 shared publication - Ayşe HazırBulan
Gynecologic Oncology Clinic, Basakşehir Cam and Sakura City Hospital, Istanbul 34480, Turkey
1 shared publication Ayşe Zehra Özdemir
1 shared publication- Basak Ozge Kayan
Department of Gynecologic Oncology, Başakşehir Çam and Sakura City Hospital, 34480 Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 25 October 2026
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 8 (6) , 1298-1307
Clinical characteristics, treatment outcomes, and factors associated with postmolar gestational trophoblastic neoplasia in patients with hydatidiform mole: a single-center retrospective cohort study
Aims: This study evaluated the clinical, laboratory, ultrasonographic, histopathological, treatment, and follow-up characteristics of patients with molar pregnancy and assessed the clinical relevance of baseline factors associated with the development of postmolar gestational trophoblastic neoplasia (GTN) in a contemporary single-center cohort.Methods: This retrospective cohort included 259 patients with hydatidiform mole. Demographic, clinical, laboratory, ultrasonographic, histopathological, treatment, and follow-up data were reviewed. Patients with unknown GTN status were excluded from comparative analyses. Group comparisons used the Mann-Whitney U, Chi-square, or Fisher’s exact test. Multivariable logistic regression was used to evaluate factors independently associated with postmolar GTN development. Firth-penalized logistic regression and a sensitivity analysis restricted to patients with adequate follow-up were additionally performed to assess the robustness of the findings.Results: Among 259 patients, partial hydatidiform mole was diagnosed in 163 patients (62.9%), complete hydatidiform mole in 80 (30.9%), and hydatidiform mole of unspecified subtype in 16 (6.2%). Postmolar GTN developed in 39 patients (15.1%), while GTN status was unknown in 12 (4.6%). Chemotherapy was administered to 33 patients (12.7%); all received a methotrexate folinic acid regimen. Overall, normalization of beta-human chorionic gonadotropin (β-hCG) was achieved in 247 patients (95.4%). In multivariable analysis, initial β-hCG level per 100.000 mIU/ml increase (adjusted OR, 1.34; 95% CI, 1.15-1.56; p
- 25 October 2026
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 8 (6) , 1298-1307
Open AccessClinical characteristics, treatment outcomes, and factors associated with postmolar gestational trophoblastic neoplasia in patients with hydatidiform mole: a single-center retrospective cohort study
Aims: This study evaluated the clinical, laboratory, ultrasonographic, histopathological, treatment, and follow-up characteristics of patients with molar pregnancy and assessed the clinical relevance of baseline factors associated with the development of postmolar gestational trophoblastic neoplasia (GTN) in a contemporary single-center cohort.Methods: This retrospective cohort included 259 patients with hydatidiform mole. Demographic, clinical, laboratory, ultrasonographic, histopathological, treatment, and follow-up data were reviewed. Patients with unknown GTN status were excluded from comparative analyses. Group comparisons used the Mann-Whitney U, Chi-square, or Fisher’s exact test. Multivariable logistic regression was used to evaluate factors independently associated with postmolar GTN development. Firth-penalized logistic regression and a sensitivity analysis restricted to patients with adequate follow-up were additionally performed to assess the robustness of the findings.Results: Among 259 patients, partial hydatidiform mole was diagnosed in 163 patients (62.9%), complete hydatidiform mole in 80 (30.9%), and hydatidiform mole of unspecified subtype in 16 (6.2%). Postmolar GTN developed in 39 patients (15.1%), while GTN status was unknown in 12 (4.6%). Chemotherapy was administered to 33 patients (12.7%); all received a methotrexate folinic acid regimen. Overall, normalization of beta-human chorionic gonadotropin (β-hCG) was achieved in 247 patients (95.4%). In multivariable analysis, initial β-hCG level per 100.000 mIU/ml increase (adjusted OR, 1.34; 95% CI, 1.15-1.56; p
- Open Access
- 24 October 2025
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 6 (5) , 551-556
Clinicopathologic profile of synchronous tumors in patients undergoing surgery for gynecologic malignancy: a retrospective single-center study
Aims: This study aimed to characterize tumor types and clinicopathological features of synchronous tumors in women operated for gynecologic malignancies. Methods: This retrospective, single-center study included 20 consecutive patients with a pathological diagnosis of synchronous tumors. Patient demographics, HPV/cytology findings, surgical procedures, histopathological features, treatment modalities, and early outcomes (recurrence and mortality) were collected and analyzed. Results: Mean age was 60.3 years and mean BMI was 31.6 kg/m². Hypertension and diabetes were each present in 35%. Most were HPV-negative (90%); cytology was negative in 65% (abnormalities: ASC-US 20%, ASC-H 5%, HSIL 10%). Synchronous endometrial and ovarian carcinoma (SEOC) was observed in 80% of the patients. The majority of patients had endometrioid adenocarcinoma (EAC). Among SEOC patients, 62.5% had stage I–II tumors. In these cases, histological concordance between synchronous tumors was 62.5%, while staging concordance was 75%. Conclusion: SEOC predominated with high histologic concordance between synchronous tumors. Although SEOC is typically detected at an early stage, there was significant concordance between synchronous tumors in terms of both histology and staging.
- 24 October 2025
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 6 (5) , 551-556
Open AccessClinicopathologic profile of synchronous tumors in patients undergoing surgery for gynecologic malignancy: a retrospective single-center study
Aims: This study aimed to characterize tumor types and clinicopathological features of synchronous tumors in women operated for gynecologic malignancies. Methods: This retrospective, single-center study included 20 consecutive patients with a pathological diagnosis of synchronous tumors. Patient demographics, HPV/cytology findings, surgical procedures, histopathological features, treatment modalities, and early outcomes (recurrence and mortality) were collected and analyzed. Results: Mean age was 60.3 years and mean BMI was 31.6 kg/m². Hypertension and diabetes were each present in 35%. Most were HPV-negative (90%); cytology was negative in 65% (abnormalities: ASC-US 20%, ASC-H 5%, HSIL 10%). Synchronous endometrial and ovarian carcinoma (SEOC) was observed in 80% of the patients. The majority of patients had endometrioid adenocarcinoma (EAC). Among SEOC patients, 62.5% had stage I–II tumors. In these cases, histological concordance between synchronous tumors was 62.5%, while staging concordance was 75%. Conclusion: SEOC predominated with high histologic concordance between synchronous tumors. Although SEOC is typically detected at an early stage, there was significant concordance between synchronous tumors in terms of both histology and staging.
- 28 March 2022
- Published by Academician Publishing
- p. 177-184
Jinekolojik Operasyonlarda Eras Protokolü
ERAS (Enhanced Recovery After Surgery) protokolü, jinekolojik cerrahide perioperatif dönemde uygulanan kanıta dayalı müdahalelerle ameliyat sonrası iyileşmeyi hızlandırmayı amaçlayan multidisipliner bir yaklaşımdır. Hastayı merkeze alan bu protokol; cerrah, ameliyathane ekibi ve yardımcı sağlık personelinin işbirliğini gerektirerek hospitalizasyon süresini kısaltmayı ve normal hayata dönüşü hızlandırmayı hedefler. Süreç preoperatif, intraoperatif ve postoperatif olmak üzere üç ana bölüme ayrılır. Preoperatif dönemde hasta eğitimi, sigara ve alkolün dört hafta önce bırakılması, ameliyattan 6 saat öncesine kadar katı ve 2 saat öncesine kadar sıvı gıda alımı ile karbonhidrat ağırlıklı beslenme önerilirken, rutin mekanik bağırsak hazırlığından kaçınılır. İntraoperatif dönemde kısa etkili anestezikler, bulantı-kusma profilaksisi, minimal invazif cerrahi yöntemler tercih edilir; rutin nazogastrik ve batın içi dren kullanımından kaçınılarak normotermi ve övolemi korunur. Postoperatif dönemde ise ilk 24 saat içinde IV sıvıların kesilmesi, normal diyete geçiş, sakız/müsil kullanımı, mobilizasyon, idrar sondasının çıkarılması ve multimodal non-opioid ağrı yönetimi uygulanır. Bu uygulamalar, ağrı ve opioid kullanımını azaltarak benign operasyonlar sonrası hastaların 1-2 günde taburcu olmasını sağlar. Sonuç olarak ERAS programları, cerrahi sonuçları olumsuz etkilemeden bakım maliyetlerini düşürür, hastaların yaşam kalitesini ve memnuniyetini artırır. The ERAS (Enhanced Recovery After Surgery) protocol is a multidisciplinary approach in gynecological surgery that aims to accelerate postoperative recovery through evidence-based interventions during the perioperative period. This patient-centered protocol requires the cooperation of the surgeon, operating room team, and allied healthcare personnel, targeting shorter hospitalization and a quicker return to normal life. The process is evaluated in three main phases: preoperative, intraoperative, and postoperative. In the preoperative phase, patient education, quitting smoking and alcohol four weeks prior, solid food intake up to 6 hours and liquid intake up to 2 hours before surgery, and carbohydrate-heavy nutrition are recommended, while routine mechanical bowel preparation is avoided. During the intraoperative phase, short-acting anesthetics, nausea-vomiting prophylaxis, and minimally invasive surgery are preferred; routine use of nasogastric and intraperitoneal drains is avoided while maintaining normothermia and euvolemia. In the postoperative phase, discontinuing IV fluids within 24 hours, initiating a regular diet, using chewing gum/laxatives, early mobilization, removing the urinary catheter, and multimodal non-opioid pain management are implemented. These practices decrease pain and opioid use, allowing patients to be discharged within 1-2 days after benign operations. Consequently, ERAS programs reduce healthcare costs without negatively impacting surgical outcomes, thereby increasing patient quality of life and satisfaction.
- 28 March 2022
- Published by Academician Publishing
- p. 177-184
Jinekolojik Operasyonlarda Eras Protokolü
ERAS (Enhanced Recovery After Surgery) protokolü, jinekolojik cerrahide perioperatif dönemde uygulanan kanıta dayalı müdahalelerle ameliyat sonrası iyileşmeyi hızlandırmayı amaçlayan multidisipliner bir yaklaşımdır. Hastayı merkeze alan bu protokol; cerrah, ameliyathane ekibi ve yardımcı sağlık personelinin işbirliğini gerektirerek hospitalizasyon süresini kısaltmayı ve normal hayata dönüşü hızlandırmayı hedefler. Süreç preoperatif, intraoperatif ve postoperatif olmak üzere üç ana bölüme ayrılır. Preoperatif dönemde hasta eğitimi, sigara ve alkolün dört hafta önce bırakılması, ameliyattan 6 saat öncesine kadar katı ve 2 saat öncesine kadar sıvı gıda alımı ile karbonhidrat ağırlıklı beslenme önerilirken, rutin mekanik bağırsak hazırlığından kaçınılır. İntraoperatif dönemde kısa etkili anestezikler, bulantı-kusma profilaksisi, minimal invazif cerrahi yöntemler tercih edilir; rutin nazogastrik ve batın içi dren kullanımından kaçınılarak normotermi ve övolemi korunur. Postoperatif dönemde ise ilk 24 saat içinde IV sıvıların kesilmesi, normal diyete geçiş, sakız/müsil kullanımı, mobilizasyon, idrar sondasının çıkarılması ve multimodal non-opioid ağrı yönetimi uygulanır. Bu uygulamalar, ağrı ve opioid kullanımını azaltarak benign operasyonlar sonrası hastaların 1-2 günde taburcu olmasını sağlar. Sonuç olarak ERAS programları, cerrahi sonuçları olumsuz etkilemeden bakım maliyetlerini düşürür, hastaların yaşam kalitesini ve memnuniyetini artırır. The ERAS (Enhanced Recovery After Surgery) protocol is a multidisciplinary approach in gynecological surgery that aims to accelerate postoperative recovery through evidence-based interventions during the perioperative period. This patient-centered protocol requires the cooperation of the surgeon, operating room team, and allied healthcare personnel, targeting shorter hospitalization and a quicker return to normal life. The process is evaluated in three main phases: preoperative, intraoperative, and postoperative. In the preoperative phase, patient education, quitting smoking and alcohol four weeks prior, solid food intake up to 6 hours and liquid intake up to 2 hours before surgery, and carbohydrate-heavy nutrition are recommended, while routine mechanical bowel preparation is avoided. During the intraoperative phase, short-acting anesthetics, nausea-vomiting prophylaxis, and minimally invasive surgery are preferred; routine use of nasogastric and intraperitoneal drains is avoided while maintaining normothermia and euvolemia. In the postoperative phase, discontinuing IV fluids within 24 hours, initiating a regular diet, using chewing gum/laxatives, early mobilization, removing the urinary catheter, and multimodal non-opioid pain management are implemented. These practices decrease pain and opioid use, allowing patients to be discharged within 1-2 days after benign operations. Consequently, ERAS programs reduce healthcare costs without negatively impacting surgical outcomes, thereby increasing patient quality of life and satisfaction.
- 28 March 2022
- Published by Academician Publishing
Güncel Kadın Hastalıkları ve Doğum Çalışmaları III
Akademisyen Yayınevi yöneticileri, yaklaşık 30 yıllık yayın tecrübesini, kendi tüzel kişiliklerine aktararak uzun zamandan beri, ticarî faaliyetlerini sürdürmektedir. Anılan süre içinde, başta sağlık ve sosyal bilimler, kültürel ve sanatsal konular dahil 2000 kitabı yayımlamanın gururu içindedir. Uluslararası yayınevi olmanın alt yapısını tamamlayan Akademisyen, Türkçe ve yabancı dillerde yayın yapmanın yanında, küresel bir marka yaratmanın peşindedir.Bilimsel ve düşünsel çalışmaların kalıcı belgeleri sayılan kitaplar, bilgi kayıt ortamı olarak yüzlerce yılın tanıklarıdır. Matbaanın icadıyla varoluşunu sağlam temellere oturtan kitabın geleceği, her ne kadar yeni buluşların yörüngesine taşınmış olsa da, daha uzun süre hayatımızda yer edineceği muhakkaktır.
- 28 March 2022
- Published by Academician Publishing
Güncel Kadın Hastalıkları ve Doğum Çalışmaları III
Akademisyen Yayınevi yöneticileri, yaklaşık 30 yıllık yayın tecrübesini, kendi tüzel kişiliklerine aktararak uzun zamandan beri, ticarî faaliyetlerini sürdürmektedir. Anılan süre içinde, başta sağlık ve sosyal bilimler, kültürel ve sanatsal konular dahil 2000 kitabı yayımlamanın gururu içindedir. Uluslararası yayınevi olmanın alt yapısını tamamlayan Akademisyen, Türkçe ve yabancı dillerde yayın yapmanın yanında, küresel bir marka yaratmanın peşindedir.Bilimsel ve düşünsel çalışmaların kalıcı belgeleri sayılan kitaplar, bilgi kayıt ortamı olarak yüzlerce yılın tanıklarıdır. Matbaanın icadıyla varoluşunu sağlam temellere oturtan kitabın geleceği, her ne kadar yeni buluşların yörüngesine taşınmış olsa da, daha uzun süre hayatımızda yer edineceği muhakkaktır.